Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florent Grange

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Autoimmunity Reviews|December 4, 2015
Kawasaki disease in adults: Observations in France and literature reviewJean-Baptiste Fraison, Pascal Sève, Claire Dauphin, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Eclinicalmedicine|July 15, 2024
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective StudyAdèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, et al.
Lancet (London, England)|April 27, 2023
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective studyAdèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, et al.
British Journal of Cancer|July 10, 2008
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanomaF Lesueur, M de Lichy, M Barrois, et al.
Cancers|July 24, 2021
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study GroupCandice Hober, Lisa Fredeau, Anne Pham-Ledard, et al.
Nature|October 21, 2011
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinomaCorine Bertolotto, Fabienne Lesueur, Sandy Giuliano, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Autoimmunity Reviews|December 4, 2015
Kawasaki disease in adults: Observations in France and literature reviewJean-Baptiste Fraison, Pascal Sève, Claire Dauphin, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Eclinicalmedicine|July 15, 2024
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Eclinicalmedicine|December 25, 2024
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort studyAlizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective StudyAdèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, et al.
Lancet (London, England)|April 27, 2023
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective studyAdèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, et al.
British Journal of Cancer|July 10, 2008
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanomaF Lesueur, M de Lichy, M Barrois, et al.
Cancers|July 24, 2021
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study GroupCandice Hober, Lisa Fredeau, Anne Pham-Ledard, et al.
Nature|October 21, 2011
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinomaCorine Bertolotto, Fabienne Lesueur, Sandy Giuliano, et al.
Pageof 8